{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:34:37Z","timestamp":1794558877298,"version":"4.9.1"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1038\/s41401-021-00660-1","type":"journal-article","created":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T08:02:47Z","timestamp":1620979367000},"page":"505-519","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Druggability of lipid metabolism modulation against renal fibrosis"],"prefix":"10.1038","volume":"43","author":[{"given":"Yuan-yuan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-guang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,14]]},"reference":[{"key":"660_CR1","doi-asserted-by":"crossref","unstructured":"Zhao X, Kwan JYY, Yip K, Liu PP, Liu FF. Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov. 2019:1\u201319:57\u201375.","DOI":"10.1038\/s41573-019-0040-5"},{"key":"660_CR2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev-physiol-022516-034227","volume":"80","author":"BD Humphreys","year":"2018","unstructured":"Humphreys BD. Mechanisms of renal fibrosis. Annu Rev Physiol. 2018;80:309\u201326.","journal-title":"Annu Rev Physiol"},{"key":"660_CR3","doi-asserted-by":"publisher","unstructured":"Hewitson TD, Holt SG, Smith ER. Progression of tubulointerstitial fibrosis and the chronic kidney disease phenotype\u2014role of risk factors and epigenetics. Front Pharmacol. 2017; 8:520. https:\/\/doi.org\/10.3389\/fphar.2017.00520.","DOI":"10.3389\/fphar.2017.00520"},{"key":"660_CR4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/ckj\/sfx093","volume":"11","author":"PC Wilson","year":"2017","unstructured":"Wilson PC, Kashgarian M, Moeckel G. Interstitial inflammation and interstitial fibrosis and tubular atrophy predict renal survival in lupus nephritis. Clin Kidney J. 2017;11:207\u201318.","journal-title":"Clin Kidney J"},{"key":"660_CR5","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/ndt\/gfw415","volume":"32","author":"DQ Chen","year":"2017","unstructured":"Chen DQ, Chen H, Chen L, Vaziri ND, Wang M, Li XR, et al. The link between phenotype and fatty acid metabolism in advanced chronic kidney disease.\u00a0Nephrol Dial Transplant.\u00a02017;32:1154-66.","journal-title":"Nephrol Dial Transplant"},{"key":"660_CR6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3389\/fphar.2018.00053","volume":"9","author":"F Dou","year":"2018","unstructured":"Dou F, Miao H, Wang JW, Chen L, Wang M, Chen H, et al. An integrated lipidomics and phenotype study reveals protective effect and biochemical mechanism of traditionally used alisma orientale juzepzuk in chronic kidney disease. Front Pharmacol. 2018;9:53.","journal-title":"Front Pharmacol"},{"key":"660_CR7","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.redox.2016.09.014","volume":"10","author":"H Chen","year":"2016","unstructured":"Chen H, Cao G, Chen DQ, Wang M, Vaziri ND, Zhang ZH, et al. Metabolomics insights into activated redox signaling and lipid metabolism dysfunction in chronic kidney disease progression. Redox Biol. 2016;10:168\u201378.","journal-title":"Redox Biol"},{"key":"660_CR8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nm.3762","volume":"21","author":"HM Kang","year":"2015","unstructured":"Kang HM, Ahn SH, Choi P, Ko Y-A, Han SH, Chinga F, et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med. 2015;21:37.","journal-title":"Nat Med"},{"key":"660_CR9","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1681\/ASN.2017070802","volume":"29","author":"KW Chung","year":"2018","unstructured":"Chung KW, Lee EK, Lee MK, Oh GT, Yu BP, Chung HY. Impairment of PPAR alpha and the fatty acid oxidation pathway aggravates renal fibrosis during aging. J Am Soc Nephrol. 2018;29:1223\u201337.","journal-title":"J Am Soc Nephrol"},{"key":"660_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3389\/fphar.2020.00265","volume":"11","author":"D Dorotea","year":"2020","unstructured":"Dorotea D, Koya D, Ha H. Recent insights into SREBP as a direct mediator of kidney fibrosis via lipid-independent pathways. Front Pharmacol. 2020;11:265. https:\/\/doi.org\/10.3389\/fphar.2020.00265.","journal-title":"Front Pharmacol"},{"key":"660_CR11","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/nrneph.2011.149","volume":"7","author":"Y Liu","year":"2011","unstructured":"Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol. 2011;7:684\u201396.","journal-title":"Nat Rev Nephrol"},{"key":"660_CR12","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2183\/pjab.95.033","volume":"95","author":"Y Sato","year":"2019","unstructured":"Sato Y, Yanagita M. Functional heterogeneity of resident fibroblasts in the kidney.\u00a0Proc Jpn Acad Ser B Phys Biol Sci.\u00a02019;95:468-78.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"660_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-017-0012-9","volume":"9","author":"R Qi","year":"2018","unstructured":"Qi R, Yang C. Renal tubular epithelial cells: the neglected mediator of tubulointerstitial fibrosis after injury. Cell Death Dis. 2018;9:1\u201311.","journal-title":"Cell Death Dis"},{"key":"660_CR14","doi-asserted-by":"publisher","unstructured":"Sato Y, Yanagita M. Resident fibroblasts in the kidney: a major driver of fibrosis and inflammation. Inflamm Regen. 2017;37:17. https:\/\/doi.org\/10.1186\/s41232-017-0048-3.","DOI":"10.1186\/s41232-017-0048-3"},{"key":"660_CR15","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ki.2012.211","volume":"82","author":"SA Summers","year":"2012","unstructured":"Summers SA, Gan P-Y, Dewage L, Ma FT, Ooi JD, O\u2019sullivan KM, et al. Mast cell activation and degranulation promotes renal fibrosis in experimental unilateral ureteric obstruction. Kidney Int. 2012;82:676\u201385.","journal-title":"Kidney Int"},{"key":"660_CR16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.mam.2018.06.002","volume":"65","author":"S Djudjaj","year":"2019","unstructured":"Djudjaj S, Boor P. Cellular and molecular mechanisms of kidney fibrosis. Mol Asp Med. 2019;65:16\u201336.","journal-title":"Mol Asp Med"},{"key":"660_CR17","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/978-981-13-8871-2_18","volume":"1165","author":"XM Meng","year":"2019","unstructured":"Meng XM. Inflammatory mediators and renal fibrosis. Adv Exp Med Biol. 2019;1165:381\u2013406.","journal-title":"Adv Exp Med Biol"},{"key":"660_CR18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000431214","volume":"1","author":"X-M Meng","year":"2015","unstructured":"Meng XM, Tang PMK, Li J, Lan HY. Macrophage phenotype in kidney injury and repair. Kidney Dis. 2015;1:138\u201346.","journal-title":"Kidney Dis"},{"key":"660_CR19","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1681\/ASN.2016050573","volume":"28","author":"YY Wang","year":"2017","unstructured":"Wang YY, Jiang H, Pan J, Huang XR, Wang YC, Huang HF, et al. Macrophage-to-myofibroblast transition contributes to interstitial fibrosis in chronic renal allograft injury. J Am Soc Nephrol. 2017;28:2053\u201367.","journal-title":"J Am Soc Nephrol"},{"key":"660_CR20","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.biopha.2018.02.090","volume":"101","author":"L Chen","year":"2018","unstructured":"Chen L, Yang T, Lu D-W, Zhao H, Feng Y-L, Chen H, et al. Central role of dysregulation of TGF-\u03b2\/Smad in CKD progression and potential targets of its treatment. Biomed Pharmacother. 2018;101:670\u201381.","journal-title":"Biomed Pharmacother"},{"key":"660_CR21","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymthe.2017.09.024","volume":"26","author":"M Feng","year":"2018","unstructured":"Feng M, Tang PM-K, Huang X-R, Sun S-F, You Y-K, Xiao J, et al. TGF-\u03b2 mediates renal fibrosis via the Smad3-Erbb4-IR long noncoding RNA axis. Mol Ther. 2018;26:148\u201361.","journal-title":"Mol Ther"},{"key":"660_CR22","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.bbadis.2017.11.011","volume":"1864","author":"H Li","year":"2018","unstructured":"Li H, Cai H, Deng J, Tu X, Sun Y, Huang Z, et al. TGF-\u03b2-mediated upregulation of Sox9 in fibroblast promotes renal fibrosis.\u00a0Biochim Biophys Acta Mol Basis Dis.\u00a02018;1864:520-32.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"660_CR23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.matbio.2017.12.016","volume":"68","author":"AH Gy\u00f6rfi","year":"2018","unstructured":"Gy\u00f6rfi AH, Matei AE, Distler JHW. Targeting TGF-\u03b2 signaling for the treatment of fibrosis. Matrix Biol. 2018;68-69:8\u201327.","journal-title":"Matrix Biol."},{"key":"660_CR24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fphar.2017.00461","volume":"8","author":"KL Walton","year":"2017","unstructured":"Walton KL, Johnson KE, Harrison CA. Targeting TGF-\u03b2 mediated SMAD signaling for the prevention of fibrosis. Front Pharmacol. 2017;8:461.","journal-title":"Front Pharmacol."},{"key":"660_CR25","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1681\/ASN.2009121244","volume":"21","author":"XM Meng","year":"2010","unstructured":"Meng XM, Huang XR, Chung AC, Qin W, Shao X, Igarashi P, et al. Smad2 protects against TGF-beta\/Smad3-mediated renal fibrosis. J Am Soc Nephrol. 2010;21:1477\u201387.","journal-title":"J Am Soc Nephrol"},{"key":"660_CR26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrneph.2016.48","volume":"12","author":"XM Meng","year":"2016","unstructured":"Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-beta: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12:325\u201338.","journal-title":"Nat Rev Nephrol"},{"key":"660_CR27","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrneph.2016.54","volume":"12","author":"M Edeling","year":"2016","unstructured":"Edeling M, Ragi G, Huang S, Pavenst\u00e4dt H, Susztak K. Developmental signalling pathways in renal fibrosis: the roles of Notch, Wnt and Hedgehog. Nat Rev Nephrol. 2016;12:426\u201339.","journal-title":"Nat Rev Nephrol"},{"key":"660_CR28","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1681\/ASN.2008060566","volume":"20","author":"W He","year":"2009","unstructured":"He W, Dai C, Li Y, Zeng G, Monga SP, Liu Y. Wnt\/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol. 2009;20:765\u201376.","journal-title":"J Am Soc Nephrol"},{"key":"660_CR29","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1172\/JCI43025","volume":"120","author":"B Bielesz","year":"2010","unstructured":"Bielesz B, Sirin Y, Si H, Niranjan T, Gruenwald A, Ahn S, et al. Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans. J Clin Invest. 2010;120:4040\u201354.","journal-title":"J Clin Invest"},{"key":"660_CR30","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.ajpath.2011.12.039","volume":"180","author":"SL Fabian","year":"2012","unstructured":"Fabian SL, Penchev RR, St-Jacques B, Rao AN, Sipil\u00e4 P, West KA, et al. Hedgehog-Gli pathway activation during kidney fibrosis. Am J Pathol. 2012;180:1441\u201353.","journal-title":"Am J Pathol"},{"key":"660_CR31","doi-asserted-by":"crossref","unstructured":"Rauchman M, Griggs D. Emerging strategies to disrupt the central TGF-\u03b2 axis in kidney fibrosis. Transl Res. 2019;209:90-104.","DOI":"10.1016\/j.trsl.2019.04.003"},{"key":"660_CR32","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.21725","volume":"54","author":"Y Chen","year":"2006","unstructured":"Chen Y, Shi\u2010Wen X, Eastwood M, Black CM, Denton CP, Leask A, et al. Contribution of activin receptor\u2013like kinase 5 (transforming growth factor \u03b2 receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis Rheum. 2006;54:1309\u201316.","journal-title":"Arthritis Rheum"},{"key":"660_CR33","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/359693a0","volume":"359","author":"MM Shull","year":"1992","unstructured":"Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, et al. Targeted disruption of the mouse transforming growth factor-\u03b21 gene results in multifocal inflammatory disease. Nature. 1992;359:693\u20139.","journal-title":"Nature"},{"key":"660_CR34","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.kint.2017.04.042","volume":"92","author":"JR Montford","year":"2017","unstructured":"Montford JR, Furgeson SB. A new CTGF target in renal fibrosis. Kidney Int. 2017;92:784\u20136.","journal-title":"Kidney Int"},{"key":"660_CR35","doi-asserted-by":"crossref","first-page":"F839","DOI":"10.1152\/ajprenal.00596.2018","volume":"317","author":"Y Nagai","year":"2019","unstructured":"Nagai Y, Matoba K, Kawanami D, Takeda Y, Akamine T, Ishizawa S, et al. ROCK2 regulates TGF-\u03b2-induced expression of CTGF and profibrotic genes via NF-\u03baB and cytoskeleton dynamics in mesangial cells. Am J Physiol-Ren Physiol. 2019;317:F839\u2013F51.","journal-title":"Am J Physiol-Ren Physiol"},{"key":"660_CR36","volume":"4","author":"Q Yan","year":"2018","unstructured":"Yan Q, Song Y, Zhang L, Chen Z, Yang C, Liu S, et al. Autophagy activation contributes to lipid accumulation in tubular epithelial cells during kidney fibrosis. Cell Death Discov. 2018;4:39.","journal-title":"Cell Death Discov"},{"key":"660_CR37","doi-asserted-by":"crossref","first-page":"R470","DOI":"10.1016\/j.cub.2015.04.004","volume":"25","author":"MA Welte","year":"2015","unstructured":"Welte MA. Expanding roles for lipid droplets. Curr Biol. 2015;25:R470\u201381.","journal-title":"Curr Biol"},{"key":"660_CR38","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1073\/pnas.0630588100","volume":"100","author":"LL Listenberger","year":"2003","unstructured":"Listenberger LL, Han X, Lewis SE, Cases S, Farese RV Jr., Ory DS, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci USA. 2003;100:3077\u201382.","journal-title":"Proc Natl Acad Sci USA"},{"key":"660_CR39","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40620-016-0278-5","volume":"29","author":"A Izquierdo-Lahuerta","year":"2016","unstructured":"Izquierdo-Lahuerta A, Mart\u00ednez-Garc\u00eda C, Medina-G\u00f3mez G. Lipotoxicity as a trigger factor of renal disease. J Nephrol. 2016;29:603\u201310.","journal-title":"J Nephrol"},{"key":"660_CR40","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/MNH.0b013e32833aa4ac","volume":"19","author":"IA Bobulescu","year":"2010","unstructured":"Bobulescu IA. Renal lipid metabolism and lipotoxicity. Curr Opin Nephrol Hypertens. 2010;19:393\u2013402.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"660_CR41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nm.3762","volume":"21","author":"HM Kang","year":"2015","unstructured":"Kang HM, Ahn SH, Choi P, Ko YA, Han SH, Chinga F, et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med. 2015;21:37\u201346.","journal-title":"Nat Med"},{"key":"660_CR42","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bbrc.2015.10.112","volume":"468","author":"Y Hou","year":"2015","unstructured":"Hou Y, Wu M, Wei J, Ren Y, Du C, Wu H, et al. CD36 is involved in high glucose-induced epithelial to mesenchymal transition in renal tubular epithelial cells. Biochem Biophys Res Commun. 2015;468:281\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"660_CR43","doi-asserted-by":"crossref","unstructured":"Hua W, Huang HZ, Tan LT, Wan JM, Gui HB, Zhao L, et al. CD36 mediated fatty acid-induced podocyte apoptosis via oxidative stress. PLoS One. 2015;10:e0127507.","DOI":"10.1371\/journal.pone.0127507"},{"key":"660_CR44","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.4049\/jimmunol.158.9.4389","volume":"158","author":"J Hughes","year":"1997","unstructured":"Hughes J, Liu Y, Van Damme J, Savill J. Human glomerular mesangial cell phagocytosis of apoptotic neutrophils: mediation by a novel CD36-independent vitronectin receptor\/thrombospondin recognition mechanism that is uncoupled from chemokine secretion. J Immunol. 1997;158:4389\u201397.","journal-title":"J Immunol"},{"key":"660_CR45","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/j.ajpath.2015.04.016","volume":"185","author":"S Pennathur","year":"2015","unstructured":"Pennathur S, Pasichnyk K, Bahrami NM, Zeng L, Febbraio M, Yamaguchi I, et al. The macrophage phagocytic receptor CD36 promotes fibrogenic pathways on removal of apoptotic cells during chronic kidney injury. Am J Pathol. 2015;185:2232\u201345.","journal-title":"Am J Pathol"},{"key":"660_CR46","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1089\/ars.2018.7634","volume":"31","author":"X Li","year":"2019","unstructured":"Li X, Zhang T, Geng J, Wu Z, Xu L, Liu J, et al. Advanced oxidation protein products promote lipotoxicity and tubulointerstitial fibrosis via CD36\/\u03b2-catenin pathway in diabetic nephropathy. Antioxid Redox Signal. 2019;31:521\u201338.","journal-title":"Antioxid Redox Signal"},{"key":"660_CR47","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S1388-1981(99)00137-7","volume":"1441","author":"N Abumrad","year":"1999","unstructured":"Abumrad N, Coburn C, Ibrahimi A. Membrane proteins implicated in long-chain fatty acid uptake by mammalian cells: CD36, FATP and FABPm.\u00a0Biochim Biophys Acta.\u00a01999;1441:4-13.","journal-title":"Biochim Biophys Acta"},{"key":"660_CR48","doi-asserted-by":"publisher","unstructured":"Wanders RJA, Waterham HR, Ferdinandusse S. Metabolic interplay between peroxisomes and other subcellular organelles including mitochondria and the endoplasmic reticulum.\u00a0Front Cell Dev Biol.\u00a02016;3:83. https:\/\/doi.org\/10.3389\/fcell.2015.00083.","DOI":"10.3389\/fcell.2015.00083"},{"key":"660_CR49","doi-asserted-by":"crossref","first-page":"E650","DOI":"10.1152\/ajpendo.1997.273.3.E650","volume":"273","author":"C Meyer","year":"1997","unstructured":"Meyer C, Nadkarni V, Stumvoll M, Gerich J. Human kidney free fatty acid and glucose uptake: evidence for a renal glucose-fatty acid cycle. Am J Physiol-Endocrinol Metab. 1997;273:E650.","journal-title":"Am J Physiol-Endocrinol Metab"},{"key":"660_CR50","first-page":"66","volume":"16","author":"M Wang","year":"2020","unstructured":"Wang M. Kidney miR-33 controls fatty acid oxidation.\u00a0Nat Rev Nephrol.\u00a02020;16:66. doi: 10.1038\/s41581-019-0228-2.","journal-title":"Nat Rev Nephrol"},{"key":"660_CR51","doi-asserted-by":"crossref","first-page":"47760","DOI":"10.18632\/oncotarget.10283","volume":"7","author":"X Hou","year":"2016","unstructured":"Hou X, Tian J, Geng J, Li X, Tang X, Zhang J, et al. MicroRNA-27a promotes renal tubulointerstitial fibrosis via suppressing PPAR\u03b3 pathway in diabetic nephropathy. Oncotarget. 2016;7:47760.","journal-title":"Oncotarget"},{"key":"660_CR52","doi-asserted-by":"crossref","first-page":"F1587","DOI":"10.1152\/ajprenal.00404.2009","volume":"297","author":"XX Wang","year":"2009","unstructured":"Wang XX, Jiang T, Shen Y, Adorini L, Pruzanski M, Gonzalez FJ. et al. The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. Am J Physiol Ren Physiol. 2009;297:F1587\u2013F96.","journal-title":"Am J Physiol Ren Physiol"},{"key":"660_CR53","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ebiom.2018.10.072","volume":"38","author":"Z Lyu","year":"2018","unstructured":"Lyu Z, Mao Z, Li Q, Xia Y, Liu Y, He Q, et al. PPAR\u03b3 maintains the metabolic heterogeneity and homeostasis of renal tubules.\u00a0EBioMedicine. 2018;38:178\u201390.","journal-title":"EBioMedicine"},{"key":"660_CR54","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s42255-018-0008-5","volume":"1","author":"X Zhao","year":"2019","unstructured":"Zhao X, Psarianos P, Ghoraie LS, Yip K, Goldstein D, Gilbert R, et al. Metabolic regulation of dermal fibroblasts contributes to skin extracellular matrix homeostasis and fibrosis. Nat Metab. 2019;1:147\u201357.","journal-title":"Nat Metab"},{"key":"660_CR55","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1164\/rccm.201504-0780OC","volume":"192","author":"N Xie","year":"2015","unstructured":"Xie N, Tan Z, Banerjee S, Cui H, Ge J, Liu RM, et al. Glycolytic reprogramming in myofibroblast differentiation and lung fibrosis. Am J Respir Crit Care Med. 2015;192:1462\u201374.","journal-title":"Am J Respir Crit Care Med"},{"key":"660_CR56","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.amjms.2019.02.003","volume":"357","author":"R Para","year":"2019","unstructured":"Para R, Romero F, George G, Summer R. Metabolic reprogramming as a driver of fibroblast activation in pulmonary fibrosis. Am J Med Sci. 2019;357:394\u20138.","journal-title":"Am J Med Sci"},{"key":"660_CR57","doi-asserted-by":"crossref","first-page":"25427","DOI":"10.1074\/jbc.M115.646984","volume":"290","author":"K Bernard","year":"2015","unstructured":"Bernard K, Logsdon NJ, Ravi S, Xie N, Persons BP, Rangarajan S, et al. Metabolic reprogramming is required for myofibroblast contractility and differentiation. J Biol Chem. 2015;290:25427\u201338.","journal-title":"J Biol Chem"},{"key":"660_CR58","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1161\/CIRCRESAHA.120.316958","volume":"127","author":"AA Gibb","year":"2020","unstructured":"Gibb AA, Lazaropoulos MP, Elrod JW. Myofibroblasts and fibrosis: mitochondrial and metabolic control of cellular differentiation. Circ Res. 2020;127:427\u201347.","journal-title":"Circ Res"},{"key":"660_CR59","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.3389\/fimmu.2019.02993","volume":"10","author":"A Batista-Gonzalez","year":"2019","unstructured":"Batista-Gonzalez A, Vidal R, Criollo A, Carre\u00f1o LJ. New insights on the role of lipid metabolism in the metabolic reprogramming of macrophages. Front Immunol. 2019;10:2993.","journal-title":"Front Immunol"},{"key":"660_CR60","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrneph.2017.126","volume":"13","author":"X Yang","year":"2017","unstructured":"Yang X, Okamura DM, Lu X, Chen Y, Moorhead J, Varghese Z, et al. CD36 in chronic kidney disease: novel insights and therapeutic opportunities. Nat Rev Nephrol. 2017;13:769.","journal-title":"Nat Rev Nephrol"},{"key":"660_CR61","doi-asserted-by":"publisher","unstructured":"Susztak K, Ciccone E, McCue P, Sharma K, B\u00f6ttinger EP. Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoS Med. 2005;2:e45. https:\/\/doi.org\/10.1371\/journal.pmed.0020045.","DOI":"10.1371\/journal.pmed.0020045"},{"key":"660_CR62","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/jcb.21236","volume":"101","author":"YL Yang","year":"2007","unstructured":"Yang YL, Lin SH, Chuang LY, Guh JY, Liao TN, Lee TC, et al. CD36 is a novel and potential anti\u2010fibrogenic target in albumin\u2010induced renal proximal tubule fibrosis. J Cell Biochem. 2007;101:735\u201344.","journal-title":"J Cell Biochem"},{"key":"660_CR63","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1681\/ASN.2008010009","volume":"20","author":"DM Okamura","year":"2009","unstructured":"Okamura DM, Pennathur S, Pasichnyk K, L\u00f3pez-Guisa JM, Collins S, Febbraio M, et al. CD36 regulates oxidative stress and inflammation in hypercholesterolemic CKD. J Am Soc Nephrol. 2009;20:495\u2013505.","journal-title":"J Am Soc Nephrol"},{"key":"660_CR64","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.kint.2015.12.043","volume":"89","author":"ACP Souza","year":"2016","unstructured":"Souza ACP, Bocharov AV, Baranova IN, Vishnyakova TG, Huang YG, Wilkins KJ, et al. Antagonism of scavenger receptor CD36 by 5A peptide prevents chronic kidney disease progression in mice independent of blood pressure regulation. Kidney Int. 2016;89:809\u201322.","journal-title":"Kidney Int"},{"key":"660_CR65","doi-asserted-by":"crossref","first-page":"F1006","DOI":"10.1152\/ajprenal.00021.2012","volume":"303","author":"RJ Baines","year":"2012","unstructured":"Baines RJ, Chana RS, Hall M, Febbraio M, Kennedy D, Brunskill NJ. CD36 mediates proximal tubular binding and uptake of albumin and is upregulated in proteinuric nephropathies. Am J Physiol-Ren Physiol. 2012;303:F1006\u2013F14.","journal-title":"Am J Physiol-Ren Physiol"},{"key":"660_CR66","doi-asserted-by":"publisher","unstructured":"Schlaepfer IR, Joshi M. CPT1A-mediated fat oxidation, mechanisms, and therapeutic potential. Endocrinology. 2020;161:bqz046.\u00a0https:\/\/doi.org\/10.1210\/endocr\/bqz046.","DOI":"10.1210\/endocr\/bqz046"},{"key":"660_CR67","doi-asserted-by":"crossref","unstructured":"Miguel V, Titua\u00f1a J, Herrero JI, Herrero L, Serra D, Cuevas P, et al. Renal tubule Cpt1a overexpression mitigates kidney fibrosis by restoring mitochondrial homeostasis. J Clin Invest. 2021;131:e140695.","DOI":"10.1172\/JCI140695"},{"key":"660_CR68","doi-asserted-by":"crossref","first-page":"104600","DOI":"10.1016\/j.phrs.2019.104600","volume":"152","author":"J Lee","year":"2020","unstructured":"Lee J, Hyon JY, Min JY, Huh YH, Kim HJ, Lee H, et al. Mitochondrial carnitine palmitoyltransferase 2 is involved in N\u03b5-(carboxymethyl)-lysine-mediated diabetic nephropathy. Pharmacol Res. 2020;152:104600.","journal-title":"Pharmacol Res"},{"key":"660_CR69","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1172\/JCI0215593","volume":"109","author":"JD Horton","year":"2002","unstructured":"Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109:1125\u201331.","journal-title":"J Clin Invest"},{"key":"660_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0330-6","volume":"9","author":"YA Wen","year":"2018","unstructured":"Wen YA, Xiong X, Zaytseva YY, Napier DL, Vallee E, Li AT, et al. Downregulation of SREBP inhibits tumor growth and initiation by altering cellular metabolism in colon cancer. Cell Death Dis. 2018;9:265.\u00a0https:\/\/doi.org\/10.1038\/s41419-018-0330-6.","journal-title":"Cell Death Dis"},{"key":"660_CR71","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.7150\/thno.40489","volume":"10","author":"J Chen","year":"2020","unstructured":"Chen J, Wu Z, Ding W, Xiao C, Zhang Y, Gao S, et al. SREBP1 siRNA enhance the docetaxel effect based on a bone-cancer dual-targeting biomimetic nanosystem against bone metastatic castration-resistant prostate cancer. Theranostics. 2020;10:1619.","journal-title":"Theranostics"},{"key":"660_CR72","doi-asserted-by":"crossref","first-page":"F614","DOI":"10.1152\/ajprenal.00140.2016","volume":"311","author":"M Mustafa","year":"2016","unstructured":"Mustafa M, Wang TN, Chen X, Gao B, Krepinsky JC. SREBP inhibition ameliorates renal injury after unilateral ureteral obstruction. Am J Physiol-Ren Physiol. 2016;311:F614\u2013F25.","journal-title":"Am J Physiol-Ren Physiol"},{"key":"660_CR73","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1210\/en.2018-00093","volume":"159","author":"R Van Krieken","year":"2018","unstructured":"Van Krieken R, Marway M, Parthasarathy P, Mehta N, Ingram AJ, Gao B, et al. Inhibition of SREBP with fatostatin does not attenuate early diabetic nephropathy in male mice. Endocrinology. 2018;159:1479\u201395.","journal-title":"Endocrinology"},{"key":"660_CR74","doi-asserted-by":"crossref","first-page":"18919","DOI":"10.1074\/jbc.M110650200","volume":"277","author":"L Sun","year":"2002","unstructured":"Sun L, Halaihel N, Zhang W, Rogers T, Levi M. Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem. 2002;277:18919\u201327.","journal-title":"J Biol Chem"},{"key":"660_CR75","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/bph.12057","volume":"168","author":"TH Kim","year":"2013","unstructured":"Kim TH, Eom JS, Lee CG, Yang YM, Lee YS, Kim SG. An active metabolite of oltipraz (M2) increases mitochondrial fuel oxidation and inhibits lipogenesis in the liver by dually activating AMPK. Br J Pharmacol. 2013;168:1647\u201361.","journal-title":"Br J Pharmacol"},{"key":"660_CR76","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.22887","volume":"49","author":"SH Hwahng","year":"2009","unstructured":"Hwahng SH, Ki SH, Bae EJ, Kim HE, Kim SG. Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones. Hepatology. 2009;49:1913\u201325.","journal-title":"Hepatology"},{"key":"660_CR77","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/2231-4040.90879","volume":"2","author":"S Tyagi","year":"2011","unstructured":"Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases. J Adv Pharm Technol Res. 2011;2:236\u201340.","journal-title":"J Adv Pharm Technol Res"},{"key":"660_CR78","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2217\/fca-2016-0059","volume":"13","author":"L Han","year":"2017","unstructured":"Han L, Shen W-J, Bittner S, Kraemer FB, Azhar S. PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-\u03b1. Future Cardiol. 2017;13:259\u201378.","journal-title":"Future Cardiol"},{"key":"660_CR79","doi-asserted-by":"crossref","first-page":"F122","DOI":"10.1152\/ajprenal.00352.2017","volume":"314","author":"R Lakhia","year":"2018","unstructured":"Lakhia R, Yheskel M, Flaten A, Quittner-Strom EB, Holland WL, Patel V. PPAR\u03b1 agonist fenofibrate enhances fatty acid \u03b2-oxidation and attenuates polycystic kidney and liver disease in mice. Am J Physiol-Ren Physiol. 2018;314:F122\u2013F31.","journal-title":"Am J Physiol-Ren Physiol"},{"key":"660_CR80","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/MJT.0b013e3181c08081","volume":"17","author":"V Berm\u00fadez","year":"2010","unstructured":"Berm\u00fadez V, Finol F, Parra N, Parra M, P\u00e9rez A, Pe\u00f1aranda L, et al. PPAR-gamma agonists and their role in type 2 diabetes mellitus management. Am J Ther. 2010;17:274\u201383.","journal-title":"Am J Ther"},{"key":"660_CR81","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/ki.2011.254","volume":"80","author":"P Boor","year":"2011","unstructured":"Boor P, Celec P, Martin IV, Villa L, Hodosy J, Klenovicsova K, et al. The peroxisome proliferator-activated receptor-alpha agonist, BAY PP1, attenuates renal fibrosis in rats. Kidney Int. 2011;80:1182\u201397.","journal-title":"Kidney Int"},{"key":"660_CR82","first-page":"452","volume":"75","author":"KW Chung","year":"2020","unstructured":"Chung KW, Ha S, Kim SM, Kim DH, An HJ, Lee EK, et al. PPAR alpha\/beta activation alleviates age-associated renal fibrosis in Sprague Dawley rats. J Gerontol A Biol Sci Med Sci. 2020;75:452\u20138.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"660_CR83","doi-asserted-by":"publisher","unstructured":"Wang Y, Pang L, Zhang Y, Lin J, Zhou H. Fenofibrate improved interstitial fibrosis of renal allograft through inhibited epithelial-mesenchymal transition induced by oxidative stress. Oxid Med Cell Longev. 2019; 2019:8936856. https:\/\/doi.org\/10.1155\/2019\/8936856.","DOI":"10.1155\/2019\/8936856"},{"key":"660_CR84","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3803\/EnM.2017.32.1.115","volume":"32","author":"KH Bae","year":"2017","unstructured":"Bae KH, Seo JB, Jung YA, Seo HY, Kang SH, Jeon HJ, et al. Lobeglitazone, a novel peroxisome proliferator-activated receptor \u03b3 agonist, attenuates renal fibrosis caused by unilateral ureteral obstruction in mice. Endocrinol Metab. 2017;32:115\u201323.","journal-title":"Endocrinol Metab"},{"key":"660_CR85","unstructured":"Kim HS, Bae KH, Jung GS, Ham HJ, Park BY, Choi YK, et al. Proceedings of the 19th European Congress of Endocrinology. (BioScientifica)."},{"key":"660_CR86","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-019-1431-x","volume":"20","author":"\u00c1 N\u00e9meth","year":"2019","unstructured":"N\u00e9meth \u00c1, M\u00f3zes MM, Calvier L, Hansmann G, K\u00f6k\u00e9ny G. The PPAR\u03b3 agonist pioglitazone prevents TGF-\u03b2 induced renal fibrosis by repressing EGR-1 and STAT3. BMC Nephrol. 2019;20:245.","journal-title":"BMC Nephrol"},{"key":"660_CR87","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/labinvest.2008.104","volume":"89","author":"T Kawai","year":"2009","unstructured":"Kawai T, Masaki T, Doi S, Arakawa T, Yokoyama Y, Doi T, et al. PPAR-\u03b3 agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-\u03b2. Lab Invest. 2009;89:47\u201358.","journal-title":"Lab Invest."},{"key":"660_CR88","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11596-016-1539-1","volume":"36","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Wang J, Zhou QD, Zhang CH, Li Q, Huang S, et al. Peroxisome proliferator-activated receptor-\u03b3 agonist pioglitazone fails to attenuate renal fibrosis caused by unilateral ureteral obstruction in mice. J Huazhong Univ Sci Technol [Med Sci]. 2016;36:41\u20137.","journal-title":"J Huazhong Univ Sci Technol [Med Sci]"},{"key":"660_CR89","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1152\/advan.00052.2006","volume":"30","author":"H Liang","year":"2006","unstructured":"Liang H, Ward WF. PGC-1alpha: a key regulator of energy metabolism. Adv Physiol Educ. 2006;30:145\u201351.","journal-title":"Adv Physiol Educ"},{"key":"660_CR90","doi-asserted-by":"crossref","first-page":"e12994","DOI":"10.1111\/acel.12994","volume":"18","author":"G Lee","year":"2019","unstructured":"Lee G, Uddin MJ, Kim Y, Ko M, Yu I, Ha H. PGC-1alpha, a potential therapeutic target against kidney aging. Aging Cell. 2019;18:e12994.","journal-title":"Aging Cell"},{"key":"660_CR91","first-page":"4490","volume":"17","author":"L Zhang","year":"2018","unstructured":"Zhang L, Liu J, Zhou F, Wang W, Chen N. PGC-1alpha ameliorates kidney fibrosis in mice with diabetic kidney disease through an antioxidative mechanism. Mol Med Rep. 2018;17:4490\u20138.","journal-title":"Mol Med Rep"},{"key":"660_CR92","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1681\/ASN.2017020130","volume":"28","author":"SH Han","year":"2017","unstructured":"Han SH, Wu MY, Nam BY, Park JT, Yoo TH, Kang SW, et al. PGC-1\u03b1 protects from notch-induced kidney fibrosis development. J Am Soc Nephrol. 2017;28:3312\u201322.","journal-title":"J Am Soc Nephrol"},{"key":"660_CR93","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1111\/bph.14935","volume":"177","author":"X Qin","year":"2020","unstructured":"Qin X, Jiang M, Zhao Y, Gong J, Su H, Yuan F, et al. Berberine protects against diabetic kidney disease via promoting PGC-1alpha-regulated mitochondrial energy homeostasis. Br J Pharmacol. 2020;177:3646\u201361.","journal-title":"Br J Pharmacol"},{"key":"660_CR94","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.yexcr.2018.06.016","volume":"370","author":"JL Wang","year":"2018","unstructured":"Wang JL, Chen CW, Tsai MR, Liu SF, Hung TJ, Yu Ju H, et al. Antifibrotic role of PGC-1alpha-siRNA against TGF-beta1-induced renal interstitial fibrosis. Exp Cell Res. 2018;370:160\u20137.","journal-title":"Exp Cell Res"},{"key":"660_CR95","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/CIRCRESAHA.118.314191","volume":"124","author":"TM Kaufman","year":"2019","unstructured":"Kaufman TM, Warden BA, Minnier J, Miles JR, Duell PB, Purnell JQ, et al. Application of PCSK9 inhibitors in practice. Circ Res. 2019;124:32\u20137.","journal-title":"Circ Res"},{"key":"660_CR96","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","volume":"73","author":"DM Charytan","year":"2019","unstructured":"Charytan DM, Sabatine MS, Pedersen TR, Im K, Park JG, Pineda AL, et al. Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial. J Am Coll Cardiol. 2019;73:2961\u201370.","journal-title":"J Am Coll Cardiol"},{"key":"660_CR97","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.nefro.2018.09.005","volume":"39","author":"S Gonz\u00e1lez Sanchidri\u00e1n","year":"2019","unstructured":"Gonz\u00e1lez Sanchidri\u00e1n S, Labrador G\u00f3mez PJ, Aguilar Aguilar JC, Davin Carrero E, Gallego Dom\u00ednguez S, G\u00f3mez-Martino Arroyo JR. Evolocumab for the treatment of heterozygous familial hypercholesterolemia in end-stage chronic kidney disease and dialysis. Nefrologia. 2019;39:218\u201320.","journal-title":"Nefrologia"},{"key":"660_CR98","doi-asserted-by":"crossref","first-page":"e014358","DOI":"10.1161\/JAHA.119.014358","volume":"9","author":"D Wu","year":"2020","unstructured":"Wu D, Zhou Y, Pan Y, Li C, Wang Y, Chen F, et al. Vaccine against PCSK9 improved renal fibrosis by regulating fatty acid beta-oxidation. J Am Heart Assoc. 2020;9:e014358.","journal-title":"J Am Heart Assoc"},{"key":"660_CR99","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrendo.2015.122","volume":"11","author":"GS Hotamisligil","year":"2015","unstructured":"Hotamisligil GS, Bernlohr DA. Metabolic functions of FABPs\u2014mechanisms and therapeutic implications. Nat Rev Endocrinol. 2015;11:592.","journal-title":"Nat Rev Endocrinol"},{"key":"660_CR100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-018-1236-z","volume":"10","author":"Y Qiao","year":"2019","unstructured":"Qiao Y, Liu L, Yin L, Xu L, Tang Z, Qi Y, et al. FABP4 contributes to renal interstitial fibrosis via mediating inflammation and lipid metabolism. Cell Death Dis. 2019;10:1\u201312.","journal-title":"Cell Death Dis"},{"key":"660_CR101","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1681\/ASN.2017030314","volume":"29","author":"S Khan","year":"2018","unstructured":"Khan S, Cabral PD, Schilling WP, Schmidt ZW, Uddin AN, Gingras A, et al. Kidney proximal tubule lipoapoptosis is regulated by fatty acid transporter-2 (FATP2). J Am Soc Nephrol. 2018;29:81\u201391.","journal-title":"J Am Soc Nephrol"},{"key":"660_CR102","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.kint.2018.09.023","volume":"95","author":"TM Jao","year":"2019","unstructured":"Jao TM, Nangaku M, Wu CH, Sugahara M, Saito H, Maekawa H, et al. ATF6 alpha downregulation of PPARalpha promotes lipotoxicity-induced tubulointerstitial fibrosis. Kidney Int. 2019;95:577\u201389.","journal-title":"Kidney Int"},{"key":"660_CR103","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1681\/ASN.2014121181","volume":"27","author":"J Cui","year":"2016","unstructured":"Han SH, Malaga-Dieguez L, Chinga F, Kang HM, Tao J, Reidy K, et al.\u00a0Deletion of Lkb1 in renal tubular epithelial cells leads to CKD by altering metabolism.\u00a0J Am Soc Nephrol.\u00a02016;27:439\u201353.","journal-title":"J Am Soc Nephrol"},{"key":"660_CR104","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.bbadis.2019.05.010","volume":"1865","author":"YL Feng","year":"2019","unstructured":"Feng YL, Chen H, Chen DQ, Vaziri ND, Su W, Ma SX, et al. Activated NF-kappaB\/Nrf2 and Wnt\/beta-catenin pathways are associated with lipid metabolism in CKD patients with microalbuminuria and macroalbuminuria. Biochim Biophys Acta Mol Basis Dis. 2019;1865:2317\u201332.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"660_CR105","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1111\/j.1523-1755.2004.00957.x","volume":"66","author":"GK Rangan","year":"2004","unstructured":"Rangan GK, Pippin JW, Couser WG. C5b-9 regulates peritubular myofibroblast accumulation in experimental focal segmental glomerulosclerosis. Kidney Int. 2004;66:1838\u201348.","journal-title":"Kidney Int"},{"key":"660_CR106","doi-asserted-by":"crossref","unstructured":"Cui J, Wu X, Song Y, Chen Y, Wan J. Complement C3 exacerbates renal interstitial fibrosis by facilitating the M1 macrophage phenotype in a mouse model of unilateral ureteral obstruction. Am J Physiol Renal Physiol. 2019;317:F1171\u2013F1182.","DOI":"10.1152\/ajprenal.00165.2019"},{"key":"660_CR107","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.3389\/fimmu.2018.02385","volume":"9","author":"Y Liu","year":"2018","unstructured":"Liu Y, Wang K, Liang X, Li Y, Zhang Y, Zhang C, et al. Complement C3 produced by macrophages promotes renal fibrosis via IL-17A secretion. Front Immunol. 2018;9:2385. https:\/\/doi.org\/10.3389\/fimmu.2018.02385.\u00a0","journal-title":"Front Immunol"},{"key":"660_CR108","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/ndt\/gfx336","volume":"33","author":"WH Yiu","year":"2017","unstructured":"Yiu WH, Li RX, Wong DWL, Wu HJ, Chan KW, Chan LYY, et al. Complement C5a inhibition moderates lipid metabolism and reduces tubulointerstitial fibrosis in diabetic nephropathy. Nephrol Dialysis Transplant. 2017;33:1323\u201332.","journal-title":"Nephrol Dialysis Transplant"},{"key":"660_CR109","first-page":"3810","volume":"117","author":"DF Higgins","year":"2007","unstructured":"Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y, Hohenstein B, et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest. 2007;117:3810\u201320.","journal-title":"J Clin Invest"},{"key":"660_CR110","doi-asserted-by":"crossref","first-page":"F1023","DOI":"10.1152\/ajprenal.90209.2008","volume":"295","author":"K Kimura","year":"2008","unstructured":"Kimura K, Iwano M, Higgins DF, Yamaguchi Y, Nakatani K, Harada K, et al. Stable expression of HIF-1\u03b1 in tubular epithelial cells promotes interstitial fibrosis. Am J Physiol-Ren Physiol. 2008;295:F1023\u2013F9.","journal-title":"Am J Physiol-Ren Physiol"},{"key":"660_CR111","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.celrep.2014.08.056","volume":"9","author":"K Bensaad","year":"2014","unstructured":"Bensaad K, Favaro E, Lewis CA, Peck B, Lord S, Collins JM, et al. Fatty acid uptake and lipid storage induced by HIF-1\u03b1 contribute to cell growth and survival after hypoxia-reoxygenation. Cell Rep. 2014;9:349\u201365.","journal-title":"Cell Rep"},{"key":"660_CR112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-019-2182-0","volume":"11","author":"Q Ke","year":"2020","unstructured":"Ke Q, Yuan Q, Qin N, Shi C, Luo J, Fang Y, et al. UCP2-induced hypoxia promotes lipid accumulation and tubulointerstitial fibrosis during ischemic kidney injury. Cell Death Dis. 2020;11:1\u201313.","journal-title":"Cell Death Dis"},{"key":"660_CR113","doi-asserted-by":"crossref","first-page":"e2005233","DOI":"10.1371\/journal.pbio.2005233","volume":"16","author":"S Huang","year":"2018","unstructured":"Huang S, Park J, Qiu C, Chung KW, Li SY, Sirin Y, et al. Jagged1\/Notch2 controls kidney fibrosis via Tfam-mediated metabolic reprogramming. PLoS Biol. 2018;16:e2005233.","journal-title":"PLoS Biol"},{"key":"660_CR114","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cmet.2017.01.004","volume":"25","author":"A Falkevall","year":"2017","unstructured":"Falkevall A, Mehlem A, Palombo I, Sahlgren BH, Ebarasi L, He L, et al. Reducing VEGF-B signaling ameliorates renal lipotoxicity and protects against diabetic kidney disease. Cell Metab. 2017;25:713\u201326.","journal-title":"Cell Metab"},{"key":"660_CR115","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.addr.2018.01.009","volume":"129","author":"Q Su","year":"2018","unstructured":"Su Q, Kumar V, Sud N, Mahato RI. MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis. Adv Drug Deliv Rev. 2018;129:54\u201363.","journal-title":"Adv Drug Deliv Rev"},{"key":"660_CR116","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.7150\/thno.22565","volume":"8","author":"Y Yu","year":"2018","unstructured":"Yu Y, Du H, Wei S, Feng L, Li J, Yao F, et al. Adipocyte-derived exosomal MiR-27a induces insulin resistance in skeletal muscle through repression of PPAR\u03b3. Theranostics. 2018;8:2171.","journal-title":"Theranostics"},{"key":"660_CR117","doi-asserted-by":"crossref","first-page":"12158","DOI":"10.1073\/pnas.1808855115","volume":"115","author":"C Casta\u00f1o","year":"2018","unstructured":"Casta\u00f1o C, Kalko S, Novials A, P\u00e1rrizas M. Obesity-associated exosomal miRNAs modulate glucose and lipid metabolism in mice. Proc Natl Acad Sci USA. 2018;115:12158\u201363.","journal-title":"Proc Natl Acad Sci"},{"key":"660_CR118","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.kint.2018.12.028","volume":"95","author":"M Bai","year":"2019","unstructured":"Bai M, Chen H, Ding D, Song R, Lin J, Zhang Y, et al. MicroRNA-214 promotes chronic kidney disease by disrupting mitochondrial oxidative phosphorylation. Kidney Int. 2019;95:1389\u2013404.","journal-title":"Kidney Int"},{"key":"660_CR119","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3390\/ijms18081702","volume":"18","author":"J Rysz","year":"2017","unstructured":"Rysz J, Gluba-Brz\u00f3zka A, Franczyk B, Jab\u0142onowski Z, Cia\u0142kowska-Rysz A. Novel biomarkers in the diagnosis of chronic kidney disease and the prediction of its outcome. Int J Mol Sci. 2017;18:1702.","journal-title":"Int J Mol Sci"},{"key":"660_CR120","first-page":"121ra18-ra18","volume":"4","author":"BN Chau","year":"2012","unstructured":"Chau BN, Xin C, Hartner J, Ren S, Castano AP, Linn G, et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med. 2012;4:121ra18-ra18.","journal-title":"Sci Transl Med"},{"key":"660_CR121","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1172\/JCI75852","volume":"125","author":"IG Gomez","year":"2015","unstructured":"Gomez IG, MacKenna DA, Johnson BG, Kaimal V, Roach AM, Ren S, et al. Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J Clin Invest. 2015;125:141\u201356.","journal-title":"J Clin Invest"},{"key":"660_CR122","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1096\/fj.201901599RR","volume":"34","author":"M Fierro\u2010Fern\u00e1ndez","year":"2020","unstructured":"Fierro\u2010Fern\u00e1ndez M, Miguel V, M\u00e1rquez\u2010Exp\u00f3sito L, Nuevo\u2010Tapioles C, Herrero JI, Blanco-Ruiz E, et al. MiR-9-5p protects from kidney fibrosis by metabolic reprogramming. FASEB J. 2020;34:410\u201331.","journal-title":"FASEB J"},{"key":"660_CR123","first-page":"1661","volume":"11","author":"M Cao","year":"2018","unstructured":"Cao M, Bai L, Wang D, Zhai Q, Li Y, Hai J, et al. miRNA-33 expression and its mechanism in patients and model rats with type 2 diabetic nephropathy. Int J Clin Exp Med. 2018;11:1661\u20138.","journal-title":"Int J Clin Exp Med"},{"key":"660_CR124","doi-asserted-by":"publisher","unstructured":"Price NL, Miguel V, Ding W, Singh AK, Malik S, Rotllan N, et al. Genetic deficiency or pharmacological inhibition of miR-33 protects from kidney fibrosis.\u00a0JCI Insight.\u00a02019;4:e131102. https:\/\/doi.org\/10.1172\/jci.insight.131102.","DOI":"10.1172\/jci.insight.131102"},{"key":"660_CR125","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.gpb.2015.09.006","volume":"14","author":"Y Fang","year":"2016","unstructured":"Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer.\u00a0Genomics Proteomics Bioinformatics.\u00a02016;14:42\u201354.","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"660_CR126","doi-asserted-by":"crossref","first-page":"eaat2039","DOI":"10.1126\/scitranslmed.aat2039","volume":"10","author":"P Wang","year":"2018","unstructured":"Wang P, Luo M-L, Song E, Zhou Z, Ma T, Wang J, et al. Long noncoding RNA lnc-TSI inhibits renal fibrogenesis by negatively regulating the TGF-\u03b2\/Smad3 pathway. Sci Transl Med. 2018;10:eaat2039.","journal-title":"Sci Transl Med"},{"key":"660_CR127","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.mce.2016.02.020","volume":"426","author":"M Wang","year":"2016","unstructured":"Wang M, Wang S, Yao D, Yan Q, Lu W. A novel long non-coding RNA CYP4B1-PS1-001 regulates proliferation and fibrosis in diabetic nephropathy. Mol Cell Endocrinol. 2016;426:136\u201345.","journal-title":"Mol Cell Endocrinol"},{"key":"660_CR128","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.omtn.2018.07.012","volume":"12","author":"J Wang","year":"2018","unstructured":"Wang J, Pan J, Li H, Long J, Fang F, Chen J, et al. lncRNA ZEB1-AS1 was suppressed by p53 for renal fibrosis in diabetic nephropathy. Mol Ther-Nucleic Acids. 2018;12:741\u201350.","journal-title":"Mol Ther-Nucleic Acids"},{"key":"660_CR129","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1172\/JCI87927","volume":"126","author":"J Long","year":"2016","unstructured":"Long J, Badal SS, Ye Z, Wang Y, Ayanga BA, Galvan DL, et al. Long noncoding RNA Tug1 regulates mitochondrial bioenergetics in diabetic nephropathy. J Clin Invest. 2016;126:4205\u201318.","journal-title":"J Clin Invest"},{"key":"660_CR130","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11626-018-0310-2","volume":"55","author":"Z Li","year":"2019","unstructured":"Li Z, Li Y, Li Q, Zhang Z, Jiang L, Li X. Role of miR-9-5p in preventing peripheral neuropathy in patients with rheumatoid arthritis by targeting REST\/miR-132 pathway. In Vitro Cell Dev Biol Anim. 2019;55:52\u201361.","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"660_CR131","doi-asserted-by":"publisher","unstructured":"Zhang H, Li Y, Tan Y, Liu Q, Jiang S, Liu D, et al. MiR-9-5p inhibits glioblastoma cells proliferation through directly targeting FOXP2 (Forkhead Box P2). Front Oncol. 2019;9:1176. https:\/\/doi.org\/10.3389\/fonc.2019.01176.","DOI":"10.3389\/fonc.2019.01176"},{"key":"660_CR132","first-page":"7314","volume":"23","author":"Y Wei","year":"2019","unstructured":"Wei Y, Jiao X, Zhang S, Xu Y, Li S, Kong B. MiR-9-5p could promote angiogenesis and radiosensitivity in cervical cancer by targeting SOCS5. Eur Rev Med Pharmacol Sci. 2019;23:7314\u201326.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"660_CR133","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jconrel.2019.10.007","volume":"313","author":"SWL Lee","year":"2019","unstructured":"Lee SWL, Paoletti C, Campisi M, Osaki T, Adriani G, Kamm RD, et al. MicroRNA delivery through nanoparticles. J Control Release. 2019;313:80\u201395.","journal-title":"J Control Release"},{"key":"660_CR134","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.addr.2017.12.019","volume":"129","author":"MV Nastase","year":"2018","unstructured":"Nastase MV, Zeng-Brouwers J, Wygrecka M, Schaefer L. Targeting renal fibrosis: mechanisms and drug delivery systems. Adv Drug Deliv Rev. 2018;129:295\u2013307.","journal-title":"Adv Drug Deliv Rev"},{"key":"660_CR135","doi-asserted-by":"crossref","first-page":"9880","DOI":"10.1021\/acsnano.9b03343","volume":"13","author":"H Yang","year":"2019","unstructured":"Yang H, Qin X, Wang H, Zhao X, Liu Y, Wo HT, et al. An in vivo miRNA delivery system for restoring infarcted myocardium. ACS Nano. 2019;13:9880\u201394.","journal-title":"ACS Nano"},{"key":"660_CR136","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3390\/cells9020521","volume":"9","author":"CP O\u2019Neill","year":"2020","unstructured":"O\u2019Neill CP, Dwyer RM. Nanoparticle-based delivery of tumor suppressor microRNA for cancer therapy. Cells. 2020;9:521.","journal-title":"Cells"},{"key":"660_CR137","doi-asserted-by":"crossref","first-page":"19-","DOI":"10.1186\/s13578-019-0282-2","volume":"9","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Liu Y, Liu H, Tang WH. Exosomes: biogenesis, biologic function and clinical potential. Cell Biosci. 2019;9:19. doi: 10.1186\/s13578-019-0282-2.","journal-title":"Cell Biosci"},{"key":"660_CR138","doi-asserted-by":"crossref","first-page":"e1802896","DOI":"10.1002\/adma.201802896","volume":"31","author":"B Yang","year":"2019","unstructured":"Yang B, Chen Y, Shi J. Exosome biochemistry and advanced nanotechnology for next-generation theranostic platforms. Adv Mater. 2019;31:e1802896.","journal-title":"Adv Mater"},{"key":"660_CR139","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1039\/C9NR09011H","volume":"12","author":"H Nie","year":"2020","unstructured":"Nie H, Xie X, Zhang D, Zhou Y, Li B, Li F, et al. Use of lung-specific exosomes for miRNA-126 delivery in non-small cell lung cancer. Nanoscale. 2020;12:877\u201387.","journal-title":"Nanoscale"},{"key":"660_CR140","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-46407-1","volume":"9","author":"KI Mentkowski","year":"2019","unstructured":"Mentkowski KI, Lang JK. Exosomes engineered to express a cardiomyocyte binding peptide demonstrate improved cardiac retention in vivo. Sci Rep. 2019;9:10041-.","journal-title":"Sci Rep"},{"key":"660_CR141","doi-asserted-by":"crossref","unstructured":"Chen Y, Li Z, Chen X, Zhang S. Long non-coding RNAs: from disease code to drug role. Acta Pharm Sin B. 2020;11:340-54.","DOI":"10.1016\/j.apsb.2020.10.001"},{"key":"660_CR142","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1111\/jcmm.15295","volume":"24","author":"J Jin","year":"2020","unstructured":"Jin J, Sun H, Shi C, Yang H, Wu Y, Li W, et al. Circular RNA in renal diseases. J Cell Mol Med. 2020;24:6523\u201333.","journal-title":"J Cell Mol Med"},{"key":"660_CR143","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1248\/bpb.b19-00901","volume":"43","author":"S Wen","year":"2020","unstructured":"Wen S, Li S, Li L, Fan Q. circACTR2: a novel mechanism regulating high glucose-induced fibrosis in renal tubular cells via pyroptosis. Biol Pharm Bull. 2020;43:558\u201364.","journal-title":"Biol Pharm Bull"},{"key":"660_CR144","doi-asserted-by":"crossref","unstructured":"Yu G, Yang Z, Peng T, Lv Y. Circular RNAs: rising stars in lipid metabolism and lipid disorders.\u00a0J Cell Physiol.\u00a02021;236:4797-806.\u00a0","DOI":"10.1002\/jcp.30200"},{"key":"660_CR145","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1159\/000491619","volume":"47","author":"A Li","year":"2018","unstructured":"Li A, Huang W, Zhang X, Xie L, Miao X. Identification and characterization of CircRNAs of two pig breeds as a new biomarker in metabolism-related diseases. Cell Physiol Biochem. 2018;47:2458\u201370.","journal-title":"Cell Physiol Biochem"},{"key":"660_CR146","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.7150\/thno.42417","volume":"10","author":"Y Liu","year":"2020","unstructured":"Liu Y, Liu H, Li Y, Mao R, Yang H, Zhang Y, et al. Circular RNA SAMD4A controls adipogenesis in obesity through the miR-138-5p\/EZH2 axis. Theranostics. 2020;10:4705\u201319.","journal-title":"Theranostics"},{"key":"660_CR147","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.gendis.2017.11.005","volume":"5","author":"Z He","year":"2018","unstructured":"He Z, Zhang R, Jiang F, Hou W, Hu C. Role of genetic and environmental factors in DNA methylation of lipid metabolism. Genes Dis. 2018;5:9\u201315.","journal-title":"Genes Dis"},{"key":"660_CR148","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/npp.2012.112","volume":"38","author":"LD Moore","year":"2013","unstructured":"Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology. 2013;38:23\u201338.","journal-title":"Neuropsychopharmacology"},{"key":"660_CR149","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2337\/db13-1100","volume":"63","author":"B Hidalgo","year":"2014","unstructured":"Hidalgo B, Irvin MR, Sha J, Zhi D, Aslibekyan S, Absher D, et al. Epigenome-wide association study of fasting measures of glucose, insulin, and HOMA-IR in the Genetics of Lipid Lowering Drugs and Diet Network study. Diabetes. 2014;63:801\u20137.","journal-title":"Diabetes"},{"key":"660_CR150","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.metabol.2013.10.003","volume":"63","author":"L Gillberg","year":"2014","unstructured":"Gillberg L, Jacobsen SC, R\u00f6nn T, Br\u00f8ns C, Vaag A. PPARGC1A DNA methylation in subcutaneous adipose tissue in low birth weight subjects\u2013impact of 5 days of high-fat overfeeding. Metab Clin Exp. 2014;63:263\u201371.","journal-title":"Metab Clin Exp"},{"key":"660_CR151","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1210\/jc.2009-2413","volume":"95","author":"C Br\u00f8ns","year":"2010","unstructured":"Br\u00f8ns C, Jacobsen S, Nilsson E, R\u00f6nn T, Jensen CB, Storgaard H, et al. Deoxyribonucleic acid methylation and gene expression of PPARGC1A in human muscle is influenced by high-fat overfeeding in a birth-weight-dependent manner. J Clin Endocrinol Metab. 2010;95:3048\u201356.","journal-title":"J Clin Endocrinol Metab"},{"key":"660_CR152","doi-asserted-by":"publisher","unstructured":"Principe DR, Doll JA, Bauer J, Jung B, Munshi HG, Bartholin L, et al. TGF-\u03b2: duality of function between tumor prevention and carcinogenesis.\u00a0J Natl Cancer Inst.\u00a02014;106:djt369. https:\/\/doi.org\/10.1093\/jnci\/djt369.","DOI":"10.1093\/jnci\/djt369"},{"key":"660_CR153","doi-asserted-by":"crossref","unstructured":"Kelly A, Houston SA, Sherwood E, Casulli J, Travis MA. Regulation of innate and adaptive immunity by TGF\u03b2. Adv Immunol. 2017;134:137-233.\u00a0","DOI":"10.1016\/bs.ai.2017.01.001"},{"key":"660_CR154","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1242\/jcs.107.5.1137","volume":"107","author":"M Shah","year":"1994","unstructured":"Shah M, Foreman DM, Ferguson M. Neutralising antibody to TGF-beta 1, 2 reduces cutaneous scarring in adult rodents. J Cell Sci. 1994;107:1137\u201357.","journal-title":"J Cell Sci"},{"key":"660_CR155","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hep.31000","volume":"72","author":"MM Syed-Abdul","year":"2020","unstructured":"Syed-Abdul MM, Parks EJ, Gaballah AH, Bingham K, Hammoud GM, Kemble G, et al. Fatty acid synthase inhibitor TVB-2640 reduces hepatic de novo lipogenesis in males with metabolic abnormalities. Hepatology. 2020;72:103\u201318.","journal-title":"Hepatology"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00660-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00660-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00660-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T18:54:19Z","timestamp":1699037659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00660-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,14]]},"references-count":155,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["660"],"URL":"https:\/\/doi.org\/10.1038\/s41401-021-00660-1","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,14]]},"assertion":[{"value":"11 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}